InjectionClinical Overview
Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Inject subcutaneously as directed by your diabetologist before meals. Rotate injection sites daily.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia, lipodystrophy, injection site pain. Rare/Severe: Hypoglycemic coma, severe hypokalemia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Ensure correct unit measurement. Always have glucose handy. Never share insulin pens or needles.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Biphasic Isophane Insulin Injection 40 IU/ml (30/70)
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Biphasic Isophane Insulin Injection (50:50) 40 IU per ml
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Biphasic Isophane Insulin Injection 100 IU/ml (30/70)
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Soluble Insulin Injection 100 IU per ml (R-DNA Origin)
Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.